[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650131":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":37,"responsibleParty":60,"collaborators":18,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":22,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":18,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":83,"whyStopped":18,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"National Cancer Centre, Singapore","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SPARKLE-2 Intervention","EXPERIMENTAL","Participants will receive SPARKLE-2 immediately at bi-weekly interval.",[13],"Behavioral: SPARKLE-2",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care","NO_INTERVENTION","Participants will not receive any study intervention (SPARKLE-2) and will continue to receive their usual care.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","SPARKLE-2","Patients will receive a Short Message Service (SMS) text on their phone every 2 weeks, inviting them to complete a self-reported online six-item Integrated Palliative care Outcome Scale (IPOS) questionnaire over a period of 12 months.\n\nIf a patient records higher scores on any IPOS symptom domains, a programme coordinator will then make a phone call to the patient for further assessment of symptoms and concerns identified. If indicated, the programme coordinator would then initiate management of the symptoms and concerns according to structured clinical management protocols.",[9],[26],{"name":27,"affiliation":5,"role":28},"Grace Meijuan YANG, MD, MPH, PhD","STUDY_CHAIR",[30,34],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","63065844","grace.yang.m.j@singhealth.com.sg",{"name":35,"role":31,"phone":18,"phoneExt":18,"email":36},"Jess Ng Hiv Choo","jess.ng.h.c@nccs.com.sg",[38,51],{"facility":5,"status":18,"city":39,"state":18,"zip":40,"country":39,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Singapore","168583","SG",{"type":43,"coordinates":44},"Point",[45,46],103.85007,1.28967,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":18,"phoneExt":18,"email":18},"Dr Grace Meijuan YANG, MD, MPH, PhD",{"facility":52,"status":18,"city":39,"state":18,"zip":53,"country":39,"countryCode":41,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"Singapore General Hospital","169608",{"type":43,"coordinates":55},[45,46],{"lat":46,"lon":45},[58],{"name":59,"role":31,"phone":18,"phoneExt":18,"email":18},"Dr Yi ZHOU, MD, MRCP (UK), MMed",{"type":61,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100650131","effectiveness-and-implementation-of-supportive-and-palliative-care-review-kit-in-locations-everywhere-100650131",false,"NCT07745816","Effectiveness and Implementation of 'Supportive and Palliative Care Review Kit in Locations Everywhere'","Effectiveness and Implementation of 'Supportive and Palliative cAre Review Kit in Locations Everywhere' (SPARKLE-2) - A Randomized Controlled Trial","Inclusion Criteria:\n\n* Inclusion criteria for patients:\n\n  1. 21 years old or older\n  2. Diagnosed of advanced cancer diagnosis, defined as metastatic or recurrent\u002F progressive Stage III\u002FIV solid tumour\n  3. Has an unplanned hospital admission and expected to be discharged home\n  4. Able to speak English or Mandarin Chinese or Malay\n  5. Able to provide informed consent\n\n     Additional inclusion criteria for patient participants of semi-structured interviews are:\n  6. Enrolled in the SPARKLE-2 RCT, whether randomized to the SPARKLE intervention or usual care group and regardless of fidelity to trial procedures.\n* Inclusion criteria for caregivers:\n\n  1. 21 years old or older\n  2. Self-endorsing or identified by an enrolled patient as a spouse\u002Fpartner, relative or friend who knows them well and who provides support due to their cancer\n  3. Able to speak English or Mandarin Chinese or Malay\n  4. Able to provide informed consent\n* Inclusion criteria for healthcare providers:\n\n  1. 21 years old or older\n  2. Healthcare professional who is involved in the clinical care of patients with advanced cancer for at least 50% of their work hours\n  3. Able to provide informed consent\n  4. Involved in the processes of the SPARKLE-2\n\nExclusion Criteria:\n\n* Exclusion criteria for patients:\n\n  1. Assessed by the treating physician as unable to complete study procedures\n  2. Unable to complete patient-reported outcome measures\n* Exclusion criteria for caregivers:\n\n  1\\. Unable to complete interviews\n* Exclusion criteria for healthcare providers:\n\n  1. Healthcare professionals that are not providing care for cancer patients.\n  2. Unable to complete interviews","ALL","21 Years","120 Years",{"count":73,"type":74},300,"ESTIMATED","INTERVENTIONAL",[77],"NA","Advanced cancer patients often experience significant physical and emotional symptoms, which can lead to frequent hospital visits and reduced quality of life. Although palliative care can help manage these symptoms and improve well-being, it is often introduced too late.\n\nA proactive symptom monitoring model, SPARKLE-2 aims to identify patients who need palliative care earlier by regularly checking their symptoms using a simple questionnaire. Patients with concerned symptoms will receive timely support from the palliative care team, with the goal of improving their quality of life, reducing unnecessary hospital admissions, and helping more patients receive care in the community rather than in hospital. In the earlier SPARKLE-1 study, it showed the improvement of patients' physical wellbeing. SPARKLE-2 seeks to test the effectiveness among advanced cancer patients with unplanned hospital visits while simultaneously collecting data on real-world implementation.",[80,81],"Neoplasms","Palliative Care",[22],"NOT_YET_RECRUITING","2026-07-30",{"date":86,"type":87},"2026-08-04","ACTUAL",{"date":89,"type":74},"2026-08-01",{"date":91,"type":74},"2029-03-31",{"name":5,"class":6},2]